A multicentre, randomised, double-blind, placebo-controlled clinical trial to evaluate the use of Chinese herbal medicine in the management of endometriosis: a prospective study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN19413357

Enrollment

100

Registered

2006-06-02

Start date

2004-11-15

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometriosis Urological and Genital Diseases Endometriosis

Interventions

A specific Chinese herbal formula (Endoherb) versus placebo.

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Women, aged 18 - 43 years 2. Diagnosed with endometriosis by laparoscopy and the severity staged (grade I - IV) 3. At least three months of pain measuring more than 30 mm on visual analogue scale (VAS) scale

Exclusion criteria

Exclusion criteria: 1. Menopause 2. Pregnancy 3. Liver diseases 4. Suffering from diabetes mellitus 5. Suffering from malignancies 6. Hormonal treatments 7. Anti-depressant treatments 8. Immunosuppressive conditions and treatments

Design outcomes

Primary

Measure	Time frame
Pain intensity due to endometriosis, measured quantitatively on the VAS and qualitatively as descriptive values.	—

Secondary

Measure	Time frame
1. Quality of life using the 36-item Short-Form health survey (SF-36) and a study design health survey tool 2. Serum CA 125 levels	—

Countries

Australia

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026